Vietnam
· Delayed Price · Currency is VND Imexpharm Statistics
Total Valuation
Imexpharm has a market cap or net worth of VND 7.32 trillion. The enterprise value is 7.05 trillion.
| Market Cap | 7.32T |
| Enterprise Value | 7.05T |
Important Dates
The next estimated earnings date is Friday, July 17, 2026.
| Earnings Date | Jul 17, 2026 |
| Ex-Dividend Date | Jun 9, 2025 |
Share Statistics
Imexpharm has 154.01 million shares outstanding. The number of shares has decreased by -3.92% in one year.
| Current Share Class | 154.01M |
| Shares Outstanding | 154.01M |
| Shares Change (YoY) | -3.92% |
| Shares Change (QoQ) | -10.16% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.70% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 23.51 and the forward PE ratio is 19.92.
| PE Ratio | 23.51 |
| Forward PE | 19.92 |
| PS Ratio | 3.06 |
| PB Ratio | 3.08 |
| P/TBV Ratio | 3.17 |
| P/FCF Ratio | 26.33 |
| P/OCF Ratio | 25.01 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.41, with an EV/FCF ratio of 25.39.
| EV / Earnings | 22.67 |
| EV / Sales | 2.95 |
| EV / EBITDA | 12.41 |
| EV / EBIT | 15.13 |
| EV / FCF | 25.39 |
Financial Position
The company has a current ratio of 4.55, with a Debt / Equity ratio of 0.08.
| Current Ratio | 4.55 |
| Quick Ratio | 2.53 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.35 |
| Debt / FCF | 0.72 |
| Interest Coverage | 27.80 |
Financial Efficiency
Return on equity (ROE) is 15.42% and return on invested capital (ROIC) is 17.31%.
| Return on Equity (ROE) | 15.42% |
| Return on Assets (ROA) | 10.16% |
| Return on Invested Capital (ROIC) | 17.31% |
| Return on Capital Employed (ROCE) | 18.79% |
| Weighted Average Cost of Capital (WACC) | 7.56% |
| Revenue Per Employee | 1.66B |
| Profits Per Employee | 215.46M |
| Employee Count | 1,444 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 1.92 |
Taxes
In the past 12 months, Imexpharm has paid 97.06 billion in taxes.
| Income Tax | 97.06B |
| Effective Tax Rate | 21.39% |
Stock Price Statistics
The stock price has increased by +12.70% in the last 52 weeks. The beta is 0.61, so Imexpharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | +12.70% |
| 50-Day Moving Average | 54,637.00 |
| 200-Day Moving Average | 52,388.00 |
| Relative Strength Index (RSI) | 16.63 |
| Average Volume (20 Days) | 44,465 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Imexpharm had revenue of VND 2.39 trillion and earned 311.12 billion in profits. Earnings per share was 2,020.16.
| Revenue | 2.39T |
| Gross Profit | 1.14T |
| Operating Income | 466.33B |
| Pretax Income | 453.75B |
| Net Income | 311.12B |
| EBITDA | 568.43B |
| EBIT | 466.33B |
| Earnings Per Share (EPS) | 2,020.16 |
Balance Sheet
The company has 461.81 billion in cash and 199.96 billion in debt, giving a net cash position of 261.85 billion or 1,700.22 per share.
| Cash & Cash Equivalents | 461.81B |
| Total Debt | 199.96B |
| Net Cash | 261.85B |
| Net Cash Per Share | 1,700.22 |
| Equity (Book Value) | 2.38T |
| Book Value Per Share | 15,444.17 |
| Working Capital | 1.20T |
Cash Flow
In the last 12 months, operating cash flow was 292.54 billion and capital expenditures -14.68 billion, giving a free cash flow of 277.86 billion.
| Operating Cash Flow | 292.54B |
| Capital Expenditures | -14.68B |
| Depreciation & Amortization | 102.11B |
| Net Borrowing | -189.02B |
| Free Cash Flow | 277.86B |
| FCF Per Share | 1,804.16 |
Margins
Gross margin is 47.75%, with operating and profit margins of 19.49% and 14.90%.
| Gross Margin | 47.75% |
| Operating Margin | 19.49% |
| Pretax Margin | 18.96% |
| Profit Margin | 14.90% |
| EBITDA Margin | 23.75% |
| EBIT Margin | 19.49% |
| FCF Margin | 11.61% |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 1.03%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 1.03% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 21.59% |
| Buyback Yield | 3.92% |
| Shareholder Yield | 4.95% |
| Earnings Yield | 4.25% |
| FCF Yield | 3.80% |
Stock Splits
The last stock split was on September 17, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Sep 17, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Imexpharm has an Altman Z-Score of 12.9 and a Piotroski F-Score of 6.
| Altman Z-Score | 12.9 |
| Piotroski F-Score | 6 |